Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with Kathy Ireland

Gb Sciences’ Novel #Parkinson’s Disease Medication is Featured on Worldwide Business with Kathy Ireland

• Tune in this Sunday, December 17th, 2023, at 5.30 p. m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid based medicine for the treatment of Parkinson’s disease.

Las Vegas, December 14th, 2023

Gb Sciences, Inc. (OTCQB: GBLX), a leading plant inspired #biopharmaceutical research and development company, will be featured on Worldwide Business with Kathy Ireland on Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network. Check your local listings for viewing information.

Gb Sciences recently completed a successful dose response study that supports Gb Sciences’ cannabinoid based therapy for Parkinson’s disease. Dr. Andrea Small Howard, Gb Sciences’ president and chief science officer, joins Worldwide Business with Kathy Ireland to discuss Gb Sciences’ plant inspired medicines including its cannabinoid containing Parkinson’s disease medication.

“We are honored to share recent information about our first in class, cannabinoid based treatment for the motor symptoms of Parkinson’s disease on Worldwide Business with Kathy Ireland”, says Dr. Small Howard. “Beyond that, Gb Sciences is reimagining traditional medicines by creating safe, effective, plant inspired formulations to be sold as U.S. FDA approved drugs. Gb Sciences is working towards the future of medicine, and we are thankful for the opportunity to share our mission on this platform.”

The cannabinoids in Gb Sciences’ Parkinson’s drugs are synthesized for Gb Sciences by Purisys, LLC, the global industry leader in ultra high purity, pharmaceutical grade cannabinoid supply. To optimize the dosing of these active ingredients, Gb Sciences has selected Catalent Pharma’s Zydis orally disintegrating tablets (ODT). Because greater than 50 percent of Parkinson’s patients have problems with swallowing, Zydis ODT is an effective dosing solution for Gb Sciences’ formulations designed to treat Parkinson’s patients.

As early as next year, Gb Sciences plans on filing an Investigational New Drug Application to begin first in human clinical trials. As the second most common neurodegenerative disease, the market for Parkinson’s disease (PD) treatments is expected to grow to $ 12.8 billion by 2028.

Learn more about Gb Sciences …

About Worldwide Business with Kathy Ireland

Worldwide Business with Kathy Ireland is a weekly half hour show hosted by business mogul Kathy Ireland, featuring exclusive interviews of global executives sharing their business insights and success stories that shape their industries. The show broadcasts on Fox Business Network as part of its branded content lineup. Worldwide Business with Kathy Ireland extends beyond the weekly on air program with digital content delivered on various video platforms across #social #media.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant inspired, biopharmaceutical research and development company creating patented, disease targeted formulations of #cannabis and other plant inspired therapeutic mixtures for the #prescription #drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The “plant inspired” active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains eight issued U.S. and 12 issued foreign patents, as well as 18 U.S. and 55 foreign patent pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first in #human #clinical #trial. Gb Sciences’ formulations for chronic pain, anxiety and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof of concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit here …